Study of ZGGS18 in Patients With Advanced Solid Tumors
A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors
Advanced Solid Tumor
BIOLOGICAL: ZGGS18 for Injection|BIOLOGICAL: ZGGS18 for Injection
Tolerability of ZGGS18, Dose limiting toxicity, number of participants with abnormal laboratory values and/or adverse events that are related to treatment, 28 days|Safety of ZGGS18, Number of participants with adverse events/abnormal laboratory values that are related to treatment, Through study completion, an expected average of 3 years
Pharmacokinetic characteristics of ZGGS18, Peak Plasma Concentration (Cmax), Through Phase I study completion, an expected average of 1 year|Pharmacokinetic characteristics of ZGGS18, Time to maximum concentration (Tmax), Through Phase I study completion, an expected average of 1 year|Pharmacokinetic characteristics of ZGGS18, Clearance (CL/F), Through Phase I study completion, an expected average of 1 year|Pharmacokinetic characteristics of ZGGS18, Area under drug concentration-time curve, Through Phase I study completion, an expected average of 1 year|Pharmacokinetic characteristics of ZGGS18, Elimination rate constant (Ke), Through Phase I study completion, an expected average of 1 year|Pharmacokinetic characteristics of ZGGS18, Elimination half-life (t1/2), Through Phase I study completion, an expected average of 1 year|Immunogenicity of ZGGS18, Detection of anti-drug antibodies, if positive, further detection of neutralizing antibodies. Counting the number of patients and incidence of anti-drug antibodies and neutralizing antibodies, Through study completion, an expected average of 3 years|Efficacy of ZGGS18, Objective response rate, Through study completion, an expected average of 3 years|Efficacy of ZGGS18, Progression-free survival, Through study completion, an expected average of 3 years|Efficacy of ZGGS18, Disease control rate, Through study completion, an expected average of 3 years|Efficacy of ZGGS18, Duration of response, Through study completion, an expected average of 3 years|Efficacy of ZGGS18, Time to response, Through study completion, an expected average of 3 years|Efficacy of ZGGS18, Time to progression, Through study completion, an expected average of 3 years
A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors